Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 160

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial

Open access
Jackson, Daniel J, Bacharier, Leonard B, Gergen, Peter J, Gagalis, Lisa, Calatroni, Agustin, Wellford, Stephanie, Gill, Michelle A, Stokes, Jeffrey, Liu, Andrew H, Gruchalla, Rebecca S, Cohen, Robyn T, Makhija, Melanie, Khurana Hershey, Gurjit K, O'Connor, George T, Pongracic, Jacqueline A, Sherenian, Michael G, Rivera-Spoljaric, Katherine, Zoratti, Edward M, Teach, Stephen J, Kattan, Meyer, Dutmer, Cullen M, Kim, Haejin, Lamm, Carin, Sheehan, William J, Segnitz, R Max, Dill-McFarland, Kimberly A, Visness, Cynthia M, Becker, Patrice M, Gern, James E, Sorkness, Christine A, Busse, William W, Altman, Matthew C · 2022 · The Lancet

Abstract

Background: Asthma exacerbations are major causes of morbidity in urban children and have significant short- and long-term consequences. Eosinophilic phenotype-directed therapies reduce asthma exacerbations in adults, but limited data are available in children and diverse populations. Furthermore, the molecular mechanisms underlying exacerbations prevented and persistent with immune-based therapies are not well understood. Methods: Urban children and adolescents (6-17 years) living in disadvantaged neighborhoods (n=290) with exacerbation-prone asthma (2+ exacerbations in previous year) and blood eosinophils ≥150 cells/mm3 were randomized 1:1 to mepolizumab (6-11 years: 40 mg; 12-17 years: 100 mg) or placebo injections every 4 weeks added to guideline-based care for 52 weeks. The primary outcome was the number of asthma exacerbations treated with systemic corticosteroids. Mechanisms of treatment response were assessed using nasal transcriptomic modular analysis. [ClinicalTrials.gov: NCT03292588] Findings: The annualized rate of asthma exacerbations was 0.96 (95% confidence interval [CI] 0.78-1.17) with mepolizumab and 1.30 (95% CI, 1.08-1.57) with placebo (rate ratio 0.73; 95% CI, 0.56-0.96; p=0.027). There were no significant differences in secondary outcomes, including time to first exacerbation, lung function, or composite asthma severity index (CASI). Baseline nasal airway transcriptomics identified pathways differentially associated with exacerbation risk: 3 eosinophil-associated inflammatory pathways were significantly suppressed by mepolizumab therapy and related to exacerbation risk in placebo-treated participants (p=0.0012-0.015). In contrast, 5 epithelial-associated inflammatory pathways were uniquely related to exacerbation risk in mepolizumab-treated participants (p=0.0035-0.030). Interpretation: Phenotype-directed therapy with mepolizumab in urban children with exacerbation-prone eosinophilic asthma reduced exacerbations, but did not impact other asthma outcomes. Mepolizumab response was related to pre-treatment expression of specific airway inflammatory pathways. Our evaluation linking clinical responses to airway expression of inflammatory pathways demonstrates the importance of integrated mechanistic assessments of therapeutic responses, particularly in Black and Hispanic children, who are at greatest risk for morbidity and mortality from asthma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(22)01198-9

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 160

Metadata

Authors
Jackson, D. J., Bacharier, L. B., Gergen, P. J., Gagalis, L., Calatroni, A., Wellford, S., Gill, M. A., Stokes, J., Liu, A. H., Gruchalla, R. S., Cohen, R. T., Makhija, M., Khurana Hershey, G. K., O'Connor, G. T., Pongracic, J. A., Sherenian, M. G., Rivera-Spoljaric, K., Zoratti, E. M., Teach, S. J., Kattan, M., Dutmer, C. M., Kim, H., Lamm, C., Sheehan, W. J., Segnitz, R. M., Dill-McFarland, K. A., Visness, C. M., Becker, P. M., Gern, J. E., Sorkness, C. A., Busse, W. W., & Altman, M. C.
Venue
The Lancet
Publisher
Elsevier BV
Published
2022-08
Volume
400
Issue
10351
Pages
502-511
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4290999808
Cited by
160
References
4
FWCI
16.30
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial. https://app.cochat.ai/papers/10.1016/s0140-6736(22)01198-9
The paper
Jackson, D. J., Bacharier, L. B., Gergen, P. J., Gagalis, L., Calatroni, A., Wellford, S., Gill, M. A., Stokes, J., Liu, A. H., Gruchalla, R. S., Cohen, R. T., Makhija, M., Khurana Hershey, G. K., O'Connor, G. T., Pongracic, J. A., Sherenian, M. G., Rivera-Spoljaric, K., Zoratti, E. M., Teach, S. J., . . . Altman, M. C. (2022). Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial. The Lancet. https://doi.org/10.1016/s0140-6736(22)01198-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.